Mechanisms of GLP-1 receptor agonists in HFpEF: exploring weight-dependent and independent drivers of therapeutic benefit
Thomas J, Dagan M, Wang B, Gutman S, et al.
Circ Heart Fail. Pub. Online 25 Mar 2026.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Glucagon-like peptide-1 receptor agonists and heart failure hospitalization in a real-world cardiometabolic population
Issaka Y, Abdul-Kareem H, Meyahnwi D, et al.
Am J Cardiol. Pub. Online 25 Mar 2026.
Leggi
Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study
Kim JY, Kim S, Kim JH
Diabetologia. Pub. Online 21 Mar 2026.
Leggi
Early tirzepatide use after acute myocardial infarction or ischemic stroke in patients without diabetes: a real-world propensity-matched study
Mortada I, Lee A, Quach V, et al.
Am J Cardiol. Pub. online 18 Mar 2026.
Leggi
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
Rosenstock J, Yabe D, Cox D, et al.
Lancet. Pub. online 21 Mar 2026.
Leggi
Advancing type 2 diabetes care: the role of continuous glucose monitoring in noninsulin-treated patients
Gavin JR, Virdi N
Diabetes Obes Cardiometab Care. Pub. online 16 Mar 2026.
Leggi
Polygenic background contributes to GCK-MODY clinical presentation and glycaemic variability
Murray Leech J, Arni AM, Chundru VK, et al.
Diabetologia. Pub. online 18 Mar 2026.
Leggi
Artificial intelligence in type 1 diabetes management: a scoping review of randomised controlled trials
Wu Y, Pang J, Xu S, et al.
Diabetes Obes Metab. Pub. online 19 Mar 2026.
Leggi
Dementia risk in type 1 and 2 diabetes: a nationwide population‐based comparison
Jun JE, Kim S, Jeong IK, et al.
Diabetes Obes Metab. Pub. online 19 Mar 2026.
Leggi
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Cummings JL, Atri A, Sano M, et al.
Lancet. Pub. online 19 Mar 2026.
Leggi